» Articles » PMID: 27591497

Liposarcoma: Multimodality Management and Future Targeted Therapies

Overview
Date 2016 Sep 4
PMID 27591497
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and pleomorphic liposarcoma. In all 3 groups, complete surgical resection is central in treatment aimed at cure and is based on grade. Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the myxoid/round cell liposarcoma group. The groups differ in chemosensitivity, so adjuvant chemotherapy is selectively used in histologies with metastatic potential but not in the resistant subtype dedifferentiated liposarcoma. Improved understanding of the genetic aberrations that lead to liposarcoma initiation is allowing for the rapid development of targeted therapies for liposarcoma.

Citing Articles

"Enhancing Liposarcoma Prognosis - A New Predictive Scoring System Integrating Histopathological Insights".

Ciongariu A, Tapoi D, Dumitru A, Enache V, Marin A, Creanga C Cancer Manag Res. 2025; 17:331-348.

PMID: 39990278 PMC: 11844267. DOI: 10.2147/CMAR.S504889.


Primary giant liposarcoma of the gallbladder: a case report and literature review.

Yang Y, Hou Y, Yi L, Chen C, Tang L, Hu M World J Surg Oncol. 2025; 23(1):61.

PMID: 39987143 PMC: 11846246. DOI: 10.1186/s12957-025-03711-7.


Clinico-Radiological-Pathological Correlation in a Rapidly Evolving Well-Differentiated Orbital Liposarcoma: A Case Report.

Iwasaki R, Kitaguchi Y, Hayashi S, Morimoto T, Nishida K Cureus. 2025; 17(1):e77674.

PMID: 39974236 PMC: 11835626. DOI: 10.7759/cureus.77674.


Surgical management of giant retroperitoneal liposarcoma: a case report and review of the literature.

Hassani M, Deflaoui T, Derkaoui A, Akil Y, Lakhloufi M, Jidou A J Surg Case Rep. 2025; 2025(2):rjaf056.

PMID: 39936022 PMC: 11811899. DOI: 10.1093/jscr/rjaf056.


Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study.

Liu H, Hao Q, Wang X, Cheng M, Qiu F, Zhou B Front Oncol. 2025; 14:1502945.

PMID: 39868378 PMC: 11757892. DOI: 10.3389/fonc.2024.1502945.


References
1.
Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A . Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011; 29(18):2528-33. DOI: 10.1200/JCO.2010.33.6107. View

2.
Gronchi A, Pollock R . Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011; 18(8):2107-10. DOI: 10.1245/s10434-011-1746-8. View

3.
Kooby D, Antonescu C, Brennan M, Singer S . Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol. 2003; 11(1):78-84. DOI: 10.1007/BF02524350. View

4.
Cahlon O, Brennan M, Jia X, Qin L, Singer S, Alektiar K . A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg. 2011; 255(2):343-7. PMC: 5016830. DOI: 10.1097/SLA.0b013e3182367aa7. View

5.
Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Cesne A, Blay J . Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2008; 27(1):31-7. DOI: 10.1200/JCO.2008.18.0802. View